Gamida Cell is a cell therapy company focuses on finding cures for blood cancers and serious hematologic diseases. Co.'s product candidate, omidubicel, is an investigational cell therapy designed to expand the life-saving benefits of hematopoietic stem cell transplant. In addition, Co. has applied its NAM cell expansion technology to natural killer (NK) cells, to develop its product candidate, GDA-201, an investigational, NK cell-based immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201 is being evaluated in a trial for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The GMDA stock yearly return is shown above.
The yearly return on the GMDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GMDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|